Denver/June 13, 2023 – Morris Animal Foundation is funding a new study aimed at identifying genetic markers that may increase a dog’s susceptibility to hemangiosarcoma, one of the deadliest forms of canine cancer.
The study, which is being conducted by researchers at Utrecht University in the Netherlands, uses data from the Foundation’s Golden Retriever Lifetime Study. This longitudinal study has been tracking the health of 3,000+ dogs for more than a decade. Hemangiosarcoma is the most common malignancy diagnosed in Study participants, resulting in a unique set of biological samples and data that the new research will leverage to advance knowledge of this serious disease.
“Researching the data obtained from the Golden Retriever Lifetime Study could result in the identification of the actual DNA mutations that cause the disease,” said Dr. Kim M. Boerkamp, Co-Principal Investigator with the study. “These findings could aid in the development of new therapies for the disease. Additionally, a DNA test could be developed that can be used for breeding dogs to help decrease the disease incidence in the population.”
In addition to this study, the Foundation also launched its Hemangiosarcoma Initiative, a multiyear, multimillion-dollar endeavor dedicated to funding research studies focused on hemangiosarcoma to better understand, prevent, detect and treat this aggressive and deadly cancer.
If you want to support this important initiative, consider making a donation during our Stop Cancer Furever campaign. All gifts will be doubled through June 30, thanks to Petco Love and Blue Buffalo. Together, we can Stop Cancer Furever.
About Morris Animal Foundation
Morris Animal Foundation’s mission is to bridge science and resources to advance the health of animals. Founded in 1948 and headquartered in Denver, it is one of the largest nonprofit animal health research organizations in the world, funding more than $149 million in nearly 3,000 critical studies across a broad range of species. Learn more at morrisanimalfoundation.org.
Media Contact: Annie Mehl
